Abstract

Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic urothelial carcinoma in adults.

This guidance only includes recommendations for untreated urothelial carcinoma when cisplatin-based chemotherapy is unsuitable. We are developing separate guidance for urothelial carcinoma that has progressed after platinum-containing chemotherapy.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: The guidance will be updated when the data collection period has ended (expected to be December 2020, when the final analyses of the IMvigor 130 trial are available). Atezolizumab will continue to be available through the Cancer Drugs Fund while the guidance is being updated, as part of the managed access agreement.